Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13732MR)

This product GTTS-WQ13732MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13732MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10949MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ10419MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ990MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ1481MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ4159MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ13136MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ14410MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ3199MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW